Tissue Regenix Faces Revenue Decline Amid Regulatory Challenges

Tissue Regenix ( (GB:TRX) ) has provided an announcement.

Tissue Regenix Group reported a 6% revenue decline for the first half of 2025, attributed to commercial, regulatory, and reimbursement challenges. The company’s BioRinse® and dCELL® product lines faced revenue decreases, while the gross profit margin fell to 42% due to lower production yields. Despite these setbacks, the company received CE certification for OrthoPure® XT and a European patent for dCELL® technology, and expanded its dCELL distribution network. Management changes were also announced, with new appointments and resignations. The company remains optimistic about future growth and aims to improve trading and cash flow in the long term.

The most recent analyst rating on (GB:TRX) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Tissue Regenix stock, see the GB:TRX Stock Forecast page.

Spark’s Take on GB:TRX Stock

According to Spark, TipRanks’ AI Analyst, GB:TRX is a Neutral.

The overall stock score is primarily influenced by financial performance and technical analysis. While there are signs of operational improvement, persistent net losses and negative cash flows are significant concerns. The bearish technical indicators further weigh on the score, and the negative valuation metrics reflect market caution. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on GB:TRX stock, click here.

More about Tissue Regenix

Tissue Regenix is a leading medical device company specializing in regenerative medicine. The company utilizes its patented decellularisation technology, dCELL®, to create acellular tissue scaffolds from animal and human soft tissue, which are used to repair damaged body structures without rejection. Their products address clinical needs in sports medicine, foot and ankle injuries, and wound care.

Average Trading Volume: 61,339

Technical Sentiment Signal: Sell

Current Market Cap: £15.67M

For detailed information about TRX stock, go to TipRanks’ Stock Analysis page.